阿普米司特治疗中重度生殖器银屑病:DISCREET III期随机双盲安慰剂对照试验16周结果
DISCREET是一项III期随机双盲安慰剂对照试验,评估阿普米司特30 mg每日两次治疗中重度生殖器银屑病。第16周时,阿普米司特组39.6%与安慰剂组19.5%达到改良生殖器静态医师总体评估应答(主要终点,评分0/1且较基线降低≥2分),治疗差异显著(20.1%,P = .0003)。生殖器体征症状、皮肤受累及生活质量均有改善,常见不良事件为腹泻、头痛、恶心和鼻咽炎。
要点
- 阿普米司特30 mg每日两次治疗中重度生殖器银屑病,第16周主要终点应答率39.6%,安慰剂组19.5%。
- 主要终点治疗差异为20.1%(P = .0003),差异具有统计学和临床意义。
- 常见治疗中出现的不良事件包括腹泻、头痛、恶心和鼻咽炎。
核心结论
- 阿普米司特在中重度生殖器银屑病患者中显示出统计学和临床意义的生殖器医师总体评估应答,并改善体征、症状、严重程度和生活质量。
研究设计与样本
- DISCREET为III期随机双盲安慰剂对照试验(NCT03777436),按受累体表面积<10%或≥10%分层,随机分配至阿普米司特组(n = 143)或安慰剂组(n = 146),治疗16周后进入阿普米司特扩展期,本次报告第16周结果。
主要发现
- 第16周时,阿普米司特组39.6%与安慰剂组19.5%达到改良生殖器静态医师总体评估应答(主要终点,评分0/1且较基线降低≥2分),治疗差异为20.1%(P = .0003)。
- 观察到生殖器体征和症状、皮肤受累及生活质量的改善。
- 常见治疗中出现的不良事件为腹泻、头痛、恶心和鼻咽炎。
关键数值与推荐
- 主要终点为第16周改良生殖器静态医师总体评估应答(评分0/1且较基线降低≥2分),阿普米司特组39.6% vs 安慰剂组19.5%,治疗差异20.1%(P = .0003)。
临床怎么用
- 阿普米司特30 mg每日两次可作为中重度生殖器银屑病口服系统治疗选择之一,需关注腹泻、头痛、恶心和鼻咽炎等不良事件。
局限性
- 缺乏活性对照药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genital psoriasis can be stigmatizing, is highly prevalent among patients with psoriasis, and has limited treatment options. Apremilast is a unique oral immunomodulating phosphodiesterase 4 inhibitor approved for psoriasis treatment. OBJECTIVE: To assess the efficacy and safety of apremilast 30 mg twice daily in patients with genital psoriasis. METHODS: DISCREET, a phase 3, placebo-controlled trial (NCT03777436), randomized patients with moderate-to-severe genital psoriasis (stratified by affected body surface area <10% or ≥10%) to apremilast or placebo for a 16-week period, followed by an apremilast extension period. Week 16 results are presented. RESULTS: Patients were randomized to apremilast (n = 143) or placebo (n = 146). At Week 16, 39.6% and 19.5% of apremilast and placebo patients, respectively, achieved a modified static Physician Global Assessment of Genitalia response (primary endpoint; score of 0/1, ≥2-point reduction); treatment difference was significant (20.1%, P = .0003). Improvements in genital signs and symptoms, skin involvement, and quality of life were observed. Common treatment-emergent adverse events were diarrhea, headache, nausea, and nasopharyngitis. LIMITATIONS: Lack of active-comparator. CONCLUSIONS: Apremilast demonstrated statistically and clinically meaningful genital Physician Global Assessment responses and improvement of signs, symptoms, severity, and quality of life in this first randomized, controlled study of an oral systemic treatment in patients with genital psoriasis.
引用
- Merola JF, Parish LC, Guenther L, et al. Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2023. PMID: 37852306. doi:10.1016/j.jaad.2023.10.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。